A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy

Simple item page
dc.contributor.authorShen, Z.
dc.contributor.authorWei, W.
dc.contributor.authorTanaka, H.
dc.contributor.authorKohama, K.
dc.contributor.authorMa, G.
dc.contributor.authorDobashi, T.
dc.contributor.authorMaki, Y.
dc.contributor.authorWang, H.
dc.contributor.authorBi, J.
dc.contributor.authorDai, S.
dc.date.issued2011
dc.description.abstractIn order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy.
dc.description.statementofresponsibilityZheyu Shen, Wei Wei, Hideyuki Tanaka, Kazuhiro Kohama, Guanghui Ma, Toshiaki Dobashi, Yasuyuki Maki, Honghui Wang, Jingxiu Bi, Sheng Dai
dc.identifier.citationPharmacological Research, 2011; 64(4):410-419
dc.identifier.doi10.1016/j.phrs.2011.06.015
dc.identifier.issn1043-6618
dc.identifier.issn1096-1186
dc.identifier.orcidBi, J. [0000-0001-7056-8572]
dc.identifier.urihttp://hdl.handle.net/2440/68386
dc.language.isoen
dc.publisherAcademic Press Ltd
dc.relation.granthttp://purl.org/au-research/grants/arc/DP110102877
dc.rightsCopyright © 2011 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.phrs.2011.06.015
dc.subjectGalactosamine
dc.subjectDrug delivery carrier
dc.subjectTargeted therapy
dc.subjectLiver cancer
dc.titleA galactosamine-mediated drug delivery carrier for targeted liver cancer therapy
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Chemical Engineering publications